trending Market Intelligence /marketintelligence/en/news-insights/trending/A64aDoIffgqEeaiVs3f1mg2 content esgSubNav
In This List

Court upholds Sexing Technologies' semen technology patents over Genus

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Court upholds Sexing Technologies' semen technology patents over Genus

A federal jury has found that Genus PLC's sexing semen technology infringed three patents owned by Inguran LLC.

Additionally, the jury for the U.S. District Court for the Western District of Wisconsin determined that Inguran, which does business as Sexing Technologies, did not breach a 2012 agreement between the companies.

Genus unit ABS Global Inc., which sells sexed semen technology under the IntelliGen brand, will pay a royalty of $1.25 for each straw of sexed semen produced in the U.S. for infringing on one of the patents. ABS will also have to pay $2.60 in royalties for every straw sold in the U.S. up to June 30 for infringing on the remaining two patents.

ABS is looking at its options for appeal, Genus said in a Sept. 11 press release.

The litigation is part of a long-running dispute that began in 2014 between the companies over a sexed semen technology that allows farmers to breed bovine calves of the desired sex.